Toronto - Delayed Quote CAD

Apotex Health Corp. (APTX.TO)

33.40 -0.27 (-0.80%)

At close: October 30 at 4:00:00 PM EDT

Chart Range Bar

Loading chart for APTX.TO

Previous Close 33.67
Open 33.79
Bid 33.15 x --
Ask 33.60 x --
Day's Range 33.17 - 34.25
52 Week Range 26.05 - 40.18
Volume 333,850
Avg. Volume 466,343
Market Cap (intraday) 7.632B
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -0.14
Earnings Date Nov 12, 2026
Forward Dividend & Yield 0.06 (0.18%)
Ex-Dividend Date Sep 15, 2026
1y Target Est 41.37

Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. Apotex Health Corp. has a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. The company was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC.

www.apotex.com

6,000

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

APTX.TO

19.29%

S&P/TSX Composite index (^GSPTSE)

11.78%

1-Year Return

APTX.TO

19.29%

S&P/TSX Composite index (^GSPTSE)

18.03%

3-Year Return

APTX.TO

19.29%

S&P/TSX Composite index (^GSPTSE)

88.90%

5-Year Return

APTX.TO

19.29%

S&P/TSX Composite index (^GSPTSE)

69.32%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY27

Revenue 847.98M

Earnings -38.34M

Profit Margin -4.52%

FY27

200M

400M

600M

800M

-4.5%

Analyst Price Targets

40.00

41.37 Average

33.40 Current

44.30 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-0.85%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

3.2B
Net Income Avi to Common (ttm)

-27.27M
Diluted EPS (ttm)

-0.14

Balance Sheet and Cash Flow

Total Cash (mrq)

258.76M
Total Debt/Equity (mrq)

863.10%
Levered Free Cash Flow (ttm)

--

XNDU.TO Xanadu Quantum Technologies Limited

4.0500 -6.90%

ATRL.TO AtkinsRéalis Group Inc.

86.33 -2.57%

PRL.TO Propel Holdings Inc.

26.20 +0.27%

MDA.TO MDA Space Ltd.

38.00 -6.79%

HPS-A.TO Hammond Power Solutions Inc.

229.88 -6.18%

U.S. markets open in 4h 32m

Apotex Health Corp. (APTX.TO)

4.18%

7.29%

19.29%

19.29%

19.29%

19.29%

19.29%

Apotex Health Corp. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch